ABT-773：药代动力学以及与雷尼替丁和硫糖铝的相互作用。
ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
作者信息
Pletz M W, Preechachatchaval V, Bulitta J, Allewelt M, Burkhardt O, Lode H
机构信息
Department of Chest and Infectious Diseases, E. von Behring City Hospital, Free University of Berlin, Germany.
出版信息
Antimicrob Agents Chemother. 2003 Mar;47(3):1129-31. doi: 10.1128/AAC.47.3.1129-1131.2003.
We assessed the pharmacokinetics and interaction of ABT-773 in 12 volunteers receiving ABT-773 alone or concomitantly with ranitidine or sucralfate. Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng. h/ml. Coadministration of ranitidine, reduced the C(max) (-25.7%) and AUC(0- infinity ) (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773.
我们评估了12名志愿者单独服用ABT-773或同时服用雷尼替丁或硫糖铝时ABT-773的药代动力学及相互作用。150毫克ABT-773的数据如下：血浆中药物的最大浓度（C(max)）为318纳克/毫升，其半衰期为5.66小时，血浆浓度-时间曲线从0小时至无穷大的面积（AUC(0-无穷大)）为1662纳克·小时/毫升。雷尼替丁的共同给药显著降低了C(max)（-25.7%）和AUC(0-无穷大)（-15.8%）。硫糖铝对ABT-773的生物利用度没有影响。
Zotero 插件